APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Spasmolytic Injections

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Spasmolytic Injections Market Analysis and Forecast 2026-2032

Report ID 174037140230 December 2025204 pages

Choose your research edition.

Industry ResearchSpasmolytic Injections Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Spasmolytic Injections Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Spasmolytic Injections Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Spasmolytic Injections Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Spasmolytic Injections Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Spasmolytic Injections market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Spasmolytic Injections is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Spasmolytic Injections is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Spasmolytic Injections is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Spasmolytic Injections is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Spasmolytic Injections include AdvaCare Pharma, Allergan, Baxter International, Boehringer Ingelheim, Chengdu Better Pharmaceutical, CNS Therapeutics, Huarun Shuanghe, Ipsen and Medytox, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Spasmolytic Injections, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Spasmolytic Injections, also provides the revenue of main regions and countries. Of the upcoming market potential for Spasmolytic Injections, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Spasmolytic Injections revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Spasmolytic Injections market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Spasmolytic Injections revenue, projected growth trends, production technology, application and end-user industry.

Spasmolytic Injections Segment by Company

AdvaCare Pharma

Allergan

Baxter International

Boehringer Ingelheim

Chengdu Better Pharmaceutical

CNS Therapeutics

Huarun Shuanghe

Ipsen

Medytox

Nanjing Hangsheng Pharmaceutical

Sun Pharmaceutical Industries

Wanbangde Pharmaceutical Group

Wuhan Renfu Pharmaceutical

Zydus Cadila

Lilly

Mylan

Sanofi

Teva Pharmaceuticals

Spasmolytic Injections Segment by Type

Papaverines

Anticholinergics

Calcium Channel Blockers

Others

Spasmolytic Injections Segment by Application

Hospital

Clinic

Spasmolytic Injections Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Spasmolytic Injections market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Spasmolytic Injections and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Spasmolytic Injections.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Spasmolytic Injections in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Spasmolytic Injections company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Spasmolytic Injections revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Spasmolytic Injections Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Papaverines Major Player Table 3. Anticholinergics Major Player Table 4. Calcium Channel Blockers Major Player Table 5. Others Major Player Table 6. Global Spasmolytic Injections Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Clinic Major Player Table 9. Spasmolytic Injections Industry Trends Table 10. Spasmolytic Injections Industry Drivers Table 11. Spasmolytic Injections Industry Opportunities and Challenges Table 12. Spasmolytic Injections Industry Restraints Table 13. Global Spasmolytic Injections Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Spasmolytic Injections Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Spasmolytic Injections Market Share by Region (2021-2026) Table 16. Global Spasmolytic Injections Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Spasmolytic Injections Market Share by Region (2027-2032) Table 18. Global Spasmolytic Injections Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Spasmolytic Injections Revenue Market Share by Players (2021-2026) Table 20. Global Spasmolytic Injections Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Spasmolytic Injections Key Players Headquarters & Area Served Table 22. Global Spasmolytic Injections Players, Product Type & Application Table 23. Global Spasmolytic Injections Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Spasmolytic Injections by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Spasmolytic Injections Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Spasmolytic Injections Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Spasmolytic Injections Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Spasmolytic Injections Revenue Market Share by Type (2021-2026) Table 30. Global Spasmolytic Injections Revenue Market Share by Type (2027-2032) Table 31. Global Spasmolytic Injections Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Spasmolytic Injections Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Spasmolytic Injections Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Spasmolytic Injections Revenue Market Share by Application (2021-2026) Table 35. Global Spasmolytic Injections Revenue Market Share by Application (2027-2032) Table 36. AdvaCare Pharma Company Information Table 37. AdvaCare Pharma Business Overview Table 38. AdvaCare Pharma Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. AdvaCare Pharma Spasmolytic Injections Product Portfolio Table 40. AdvaCare Pharma Recent Development Table 41. Allergan Company Information Table 42. Allergan Business Overview Table 43. Allergan Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Allergan Spasmolytic Injections Product Portfolio Table 45. Allergan Recent Development Table 46. Baxter International Company Information Table 47. Baxter International Business Overview Table 48. Baxter International Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Baxter International Spasmolytic Injections Product Portfolio Table 50. Baxter International Recent Development Table 51. Boehringer Ingelheim Company Information Table 52. Boehringer Ingelheim Business Overview Table 53. Boehringer Ingelheim Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Boehringer Ingelheim Spasmolytic Injections Product Portfolio Table 55. Boehringer Ingelheim Recent Development Table 56. Chengdu Better Pharmaceutical Company Information Table 57. Chengdu Better Pharmaceutical Business Overview Table 58. Chengdu Better Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Chengdu Better Pharmaceutical Spasmolytic Injections Product Portfolio Table 60. Chengdu Better Pharmaceutical Recent Development Table 61. CNS Therapeutics Company Information Table 62. CNS Therapeutics Business Overview Table 63. CNS Therapeutics Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. CNS Therapeutics Spasmolytic Injections Product Portfolio Table 65. CNS Therapeutics Recent Development Table 66. Huarun Shuanghe Company Information Table 67. Huarun Shuanghe Business Overview Table 68. Huarun Shuanghe Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Huarun Shuanghe Spasmolytic Injections Product Portfolio Table 70. Huarun Shuanghe Recent Development Table 71. Ipsen Company Information Table 72. Ipsen Business Overview Table 73. Ipsen Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Ipsen Spasmolytic Injections Product Portfolio Table 75. Ipsen Recent Development Table 76. Medytox Company Information Table 77. Medytox Business Overview Table 78. Medytox Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Medytox Spasmolytic Injections Product Portfolio Table 80. Medytox Recent Development Table 81. Nanjing Hangsheng Pharmaceutical Company Information Table 82. Nanjing Hangsheng Pharmaceutical Business Overview Table 83. Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Product Portfolio Table 85. Nanjing Hangsheng Pharmaceutical Recent Development Table 86. Sun Pharmaceutical Industries Company Information Table 87. Sun Pharmaceutical Industries Business Overview Table 88. Sun Pharmaceutical Industries Spasmolytic Injections Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 89. Sun Pharmaceutical Industries Spasmolytic Injections Product Portfolio Table 90. Sun Pharmaceutical Industries Recent Development Table 91. Wanbangde Pharmaceutical Group Company Information Table 92. Wanbangde Pharmaceutical Group Business Overview Table 93. Wanbangde Pharmaceutical Group Spasmolytic Injections Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 94. Wanbangde Pharmaceutical Group Spasmolytic Injections Product Portfolio Table 95. Wanbangde Pharmaceutical Group Recent Development Table 96. Wuhan Renfu Pharmaceutical Company Information Table 97. Wuhan Renfu Pharmaceutical Business Overview Table 98. Wuhan Renfu Pharmaceutical Spasmolytic Injections Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 99. Wuhan Renfu Pharmaceutical Spasmolytic Injections Product Portfolio Table 100. Wuhan Renfu Pharmaceutical Recent Development Table 101. Zydus Cadila Company Information Table 102. Zydus Cadila Business Overview Table 103. Zydus Cadila Spasmolytic Injections Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 104. Zydus Cadila Spasmolytic Injections Product Portfolio Table 105. Zydus Cadila Recent Development Table 106. Lilly Company Information Table 107. Lilly Business Overview Table 108. Lilly Spasmolytic Injections Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 109. Lilly Spasmolytic Injections Product Portfolio Table 110. Lilly Recent Development Table 111. Mylan Company Information Table 112. Mylan Business Overview Table 113. Mylan Spasmolytic Injections Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 114. Mylan Spasmolytic Injections Product Portfolio Table 115. Mylan Recent Development Table 116. Sanofi Company Information Table 117. Sanofi Business Overview Table 118. Sanofi Spasmolytic Injections Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 119. Sanofi Spasmolytic Injections Product Portfolio Table 120. Sanofi Recent Development Table 121. Teva Pharmaceuticals Company Information Table 122. Teva Pharmaceuticals Business Overview Table 123. Teva Pharmaceuticals Spasmolytic Injections Sales (L), Revenue (US$ Million), Price (US$/ml) and Gross Margin (2021-2026) Table 124. Teva Pharmaceuticals Spasmolytic Injections Product Portfolio Table 125. Teva Pharmaceuticals Recent Development Table 126. North America Spasmolytic Injections Revenue by Type (2021-2026) & (US$ Million) Table 127. North America Spasmolytic Injections Revenue by Type (2027-2032) & (US$ Million) Table 128. North America Spasmolytic Injections Revenue by Application (2021-2026) & (US$ Million) Table 129. North America Spasmolytic Injections Revenue by Application (2027-2032) & (US$ Million) Table 130. North America Spasmolytic Injections Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 131. North America Spasmolytic Injections Revenue by Country (2021-2026) & (US$ Million) Table 132. North America Spasmolytic Injections Revenue by Country (US$ Million) & (2027-2032) Table 133. Europe Spasmolytic Injections Revenue by Type (2021-2026) & (US$ Million) Table 134. Europe Spasmolytic Injections Revenue by Type (2027-2032) & (US$ Million) Table 135. Europe Spasmolytic Injections Revenue by Application (2021-2026) & (US$ Million) Table 136. Europe Spasmolytic Injections Revenue by Application (2027-2032) & (US$ Million) Table 137. Europe Spasmolytic Injections Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Europe Spasmolytic Injections Revenue by Country (2021-2026) & (US$ Million) Table 139. Europe Spasmolytic Injections Revenue by Country (US$ Million) & (2027-2032) Table 140. China Spasmolytic Injections Revenue by Type (2021-2026) & (US$ Million) Table 141. China Spasmolytic Injections Revenue by Type (2027-2032) & (US$ Million) Table 142. China Spasmolytic Injections Revenue by Application (2021-2026) & (US$ Million) Table 143. China Spasmolytic Injections Revenue by Application (2027-2032) & (US$ Million) Table 144. Asia Spasmolytic Injections Revenue by Type (2021-2026) & (US$ Million) Table 145. Asia Spasmolytic Injections Revenue by Type (2027-2032) & (US$ Million) Table 146. Asia Spasmolytic Injections Revenue by Application (2021-2026) & (US$ Million) Table 147. Asia Spasmolytic Injections Revenue by Application (2027-2032) & (US$ Million) Table 148. Asia Spasmolytic Injections Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Asia Spasmolytic Injections Revenue by Region (US$ Million) & (2021-2026) Table 150. Asia Spasmolytic Injections Revenue by Region (US$ Million) & (2027-2032) Table 151. SAMEA Spasmolytic Injections Revenue by Type (2021-2026) & (US$ Million) Table 152. SAMEA Spasmolytic Injections Revenue by Type (2027-2032) & (US$ Million) Table 153. SAMEA Spasmolytic Injections Revenue by Application (2021-2026) & (US$ Million) Table 154. SAMEA Spasmolytic Injections Revenue by Application (2027-2032) & (US$ Million) Table 155. SAMEA Spasmolytic Injections Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. SAMEA Spasmolytic Injections Revenue by Country (2021-2026) & (US$ Million) Table 157. SAMEA Spasmolytic Injections Revenue by Country (US$ Million) & (2027-2032) Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Spasmolytic Injections Image Figure 2. Global Spasmolytic Injections Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Spasmolytic Injections Market Size Share 2021 VS 2025 VS 2032 Figure 4. Papaverines Image Figure 5. Anticholinergics Image Figure 6. Calcium Channel Blockers Image Figure 7. Others Image Figure 8. Global Spasmolytic Injections Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Spasmolytic Injections Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Global Spasmolytic Injections Market Size (US$ Million) & (2021-2032) Figure 13. Global Spasmolytic Injections Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Spasmolytic Injections Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Spasmolytic Injections Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Spasmolytic Injections Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Spasmolytic Injections Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Spasmolytic Injections Revenue Market Share by Type (2021-2032) Figure 20. Global Spasmolytic Injections Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Spasmolytic Injections Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Spasmolytic Injections Revenue Market Share by Application (2021-2032) Figure 23. North America Spasmolytic Injections Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Spasmolytic Injections Revenue Share by Type (2021-2032) Figure 25. North America Spasmolytic Injections Revenue Share by Application (2021-2032) Figure 26. North America Spasmolytic Injections Revenue Share by Country (2021-2032) Figure 27. United States Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Spasmolytic Injections Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Spasmolytic Injections Revenue Share by Type (2021-2032) Figure 32. Europe Spasmolytic Injections Revenue Share by Application (2021-2032) Figure 33. Europe Spasmolytic Injections Revenue Share by Country (2021-2032) Figure 34. Germany Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Spasmolytic Injections Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Spasmolytic Injections Revenue Share by Type (2021-2032) Figure 44. China Spasmolytic Injections Revenue Share by Application (2021-2032) Figure 45. Asia Spasmolytic Injections Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Spasmolytic Injections Revenue Share by Type (2021-2032) Figure 47. Asia Spasmolytic Injections Revenue Share by Application (2021-2032) Figure 48. Asia Spasmolytic Injections Revenue Share by Region (2021-2032) Figure 49. Japan Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Spasmolytic Injections Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Spasmolytic Injections Revenue Share by Type (2021-2032) Figure 57. SAMEA Spasmolytic Injections Revenue Share by Application (2021-2032) Figure 58. SAMEA Spasmolytic Injections Revenue Share by Country (2021-2032) Figure 59. Brazil Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Spasmolytic Injections Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Papaverines
  • Anticholinergics
  • Calcium Channel Blockers
  • Others
Applications
  • Hospital
  • Clinic
Companies covered
  • AdvaCare Pharma
  • Allergan
  • Baxter International
  • Boehringer Ingelheim
  • Chengdu Better Pharmaceutical
  • CNS Therapeutics
  • Huarun Shuanghe
  • Ipsen
  • Medytox
  • Nanjing Hangsheng Pharmaceutical
  • Sun Pharmaceutical Industries
  • Wanbangde Pharmaceutical Group
  • Wuhan Renfu Pharmaceutical
  • Zydus Cadila
  • Lilly
  • Mylan
  • Sanofi
  • Teva Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Spasmolytic Injections Market by Type
  3. 1.2.1 Global Spasmolytic Injections Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Papaverines
  5. 1.2.3 Anticholinergics
  6. 1.2.4 Calcium Channel Blockers
  7. 1.2.5 Others
  8. 1.3 Spasmolytic Injections Market by Application
  9. 1.3.1 Global Spasmolytic Injections Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Spasmolytic Injections Market Dynamics
  1. 2.1 Spasmolytic Injections Industry Trends
  2. 2.2 Spasmolytic Injections Industry Drivers
  3. 2.3 Spasmolytic Injections Industry Opportunities and Challenges
  4. 2.4 Spasmolytic Injections Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Spasmolytic Injections Market Perspective (2021-2032)
  2. 3.2 Global Spasmolytic Injections Growth Trends by Region
  3. 3.2.1 Global Spasmolytic Injections Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Spasmolytic Injections Market Size by Region (2021-2026)
  5. 3.2.3 Global Spasmolytic Injections Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Spasmolytic Injections Revenue by Players
  2. 4.1.1 Global Spasmolytic Injections Revenue by Players (2021-2026)
  3. 4.1.2 Global Spasmolytic Injections Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Spasmolytic Injections Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Spasmolytic Injections Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Spasmolytic Injections Key Players Headquarters & Area Served
  7. 4.4 Global Spasmolytic Injections Players, Product Type & Application
  8. 4.5 Global Spasmolytic Injections Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Spasmolytic Injections Market CR5 and HHI
  11. 4.6.3 2025 Spasmolytic Injections Tier 1, Tier 2, and Tier 3
5 Spasmolytic Injections Market Size by Type
  1. 5.1 Global Spasmolytic Injections Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Spasmolytic Injections Revenue by Type (2021-2032)
  3. 5.3 Global Spasmolytic Injections Revenue Market Share by Type (2021-2032)
6 Spasmolytic Injections Market Size by Application
  1. 6.1 Global Spasmolytic Injections Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Spasmolytic Injections Revenue by Application (2021-2032)
  3. 6.3 Global Spasmolytic Injections Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 AdvaCare Pharma
  2. 7.1.1 AdvaCare Pharma Company Information
  3. 7.1.2 AdvaCare Pharma Business Overview
  4. 7.1.3 AdvaCare Pharma Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  5. 7.1.4 AdvaCare Pharma Spasmolytic Injections Product Portfolio
  6. 7.1.5 AdvaCare Pharma Recent Developments
  7. 7.2 Allergan
  8. 7.2.1 Allergan Company Information
  9. 7.2.2 Allergan Business Overview
  10. 7.2.3 Allergan Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Allergan Spasmolytic Injections Product Portfolio
  12. 7.2.5 Allergan Recent Developments
  13. 7.3 Baxter International
  14. 7.3.1 Baxter International Company Information
  15. 7.3.2 Baxter International Business Overview
  16. 7.3.3 Baxter International Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Baxter International Spasmolytic Injections Product Portfolio
  18. 7.3.5 Baxter International Recent Developments
  19. 7.4 Boehringer Ingelheim
  20. 7.4.1 Boehringer Ingelheim Company Information
  21. 7.4.2 Boehringer Ingelheim Business Overview
  22. 7.4.3 Boehringer Ingelheim Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Boehringer Ingelheim Spasmolytic Injections Product Portfolio
  24. 7.4.5 Boehringer Ingelheim Recent Developments
  25. 7.5 Chengdu Better Pharmaceutical
  26. 7.5.1 Chengdu Better Pharmaceutical Company Information
  27. 7.5.2 Chengdu Better Pharmaceutical Business Overview
  28. 7.5.3 Chengdu Better Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Chengdu Better Pharmaceutical Spasmolytic Injections Product Portfolio
  30. 7.5.5 Chengdu Better Pharmaceutical Recent Developments
  31. 7.6 CNS Therapeutics
  32. 7.6.1 CNS Therapeutics Company Information
  33. 7.6.2 CNS Therapeutics Business Overview
  34. 7.6.3 CNS Therapeutics Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  35. 7.6.4 CNS Therapeutics Spasmolytic Injections Product Portfolio
  36. 7.6.5 CNS Therapeutics Recent Developments
  37. 7.7 Huarun Shuanghe
  38. 7.7.1 Huarun Shuanghe Company Information
  39. 7.7.2 Huarun Shuanghe Business Overview
  40. 7.7.3 Huarun Shuanghe Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Huarun Shuanghe Spasmolytic Injections Product Portfolio
  42. 7.7.5 Huarun Shuanghe Recent Developments
  43. 7.8 Ipsen
  44. 7.8.1 Ipsen Company Information
  45. 7.8.2 Ipsen Business Overview
  46. 7.8.3 Ipsen Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ipsen Spasmolytic Injections Product Portfolio
  48. 7.8.5 Ipsen Recent Developments
  49. 7.9 Medytox
  50. 7.9.1 Medytox Company Information
  51. 7.9.2 Medytox Business Overview
  52. 7.9.3 Medytox Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Medytox Spasmolytic Injections Product Portfolio
  54. 7.9.5 Medytox Recent Developments
  55. 7.10 Nanjing Hangsheng Pharmaceutical
  56. 7.10.1 Nanjing Hangsheng Pharmaceutical Company Information
  57. 7.10.2 Nanjing Hangsheng Pharmaceutical Business Overview
  58. 7.10.3 Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Nanjing Hangsheng Pharmaceutical Spasmolytic Injections Product Portfolio
  60. 7.10.5 Nanjing Hangsheng Pharmaceutical Recent Developments
  61. 7.11 Sun Pharmaceutical Industries
  62. 7.11.1 Sun Pharmaceutical Industries Company Information
  63. 7.11.2 Sun Pharmaceutical Industries Business Overview
  64. 7.11.3 Sun Pharmaceutical Industries Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Sun Pharmaceutical Industries Spasmolytic Injections Product Portfolio
  66. 7.11.5 Sun Pharmaceutical Industries Recent Developments
  67. 7.12 Wanbangde Pharmaceutical Group
  68. 7.12.1 Wanbangde Pharmaceutical Group Company Information
  69. 7.12.2 Wanbangde Pharmaceutical Group Business Overview
  70. 7.12.3 Wanbangde Pharmaceutical Group Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Wanbangde Pharmaceutical Group Spasmolytic Injections Product Portfolio
  72. 7.12.5 Wanbangde Pharmaceutical Group Recent Developments
  73. 7.13 Wuhan Renfu Pharmaceutical
  74. 7.13.1 Wuhan Renfu Pharmaceutical Company Information
  75. 7.13.2 Wuhan Renfu Pharmaceutical Business Overview
  76. 7.13.3 Wuhan Renfu Pharmaceutical Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Wuhan Renfu Pharmaceutical Spasmolytic Injections Product Portfolio
  78. 7.13.5 Wuhan Renfu Pharmaceutical Recent Developments
  79. 7.14 Zydus Cadila
  80. 7.14.1 Zydus Cadila Company Information
  81. 7.14.2 Zydus Cadila Business Overview
  82. 7.14.3 Zydus Cadila Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Zydus Cadila Spasmolytic Injections Product Portfolio
  84. 7.14.5 Zydus Cadila Recent Developments
  85. 7.15 Lilly
  86. 7.15.1 Lilly Company Information
  87. 7.15.2 Lilly Business Overview
  88. 7.15.3 Lilly Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Lilly Spasmolytic Injections Product Portfolio
  90. 7.15.5 Lilly Recent Developments
  91. 7.16 Mylan
  92. 7.16.1 Mylan Company Information
  93. 7.16.2 Mylan Business Overview
  94. 7.16.3 Mylan Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Mylan Spasmolytic Injections Product Portfolio
  96. 7.16.5 Mylan Recent Developments
  97. 7.17 Sanofi
  98. 7.17.1 Sanofi Company Information
  99. 7.17.2 Sanofi Business Overview
  100. 7.17.3 Sanofi Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Sanofi Spasmolytic Injections Product Portfolio
  102. 7.17.5 Sanofi Recent Developments
  103. 7.18 Teva Pharmaceuticals
  104. 7.18.1 Teva Pharmaceuticals Company Information
  105. 7.18.2 Teva Pharmaceuticals Business Overview
  106. 7.18.3 Teva Pharmaceuticals Spasmolytic Injections Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Teva Pharmaceuticals Spasmolytic Injections Product Portfolio
  108. 7.18.5 Teva Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Spasmolytic Injections Revenue (2021-2032)
  2. 8.2 North America Spasmolytic Injections Revenue by Type (2021-2032)
  3. 8.2.1 North America Spasmolytic Injections Revenue by Type (2021-2026)
  4. 8.2.2 North America Spasmolytic Injections Revenue by Type (2027-2032)
  5. 8.3 North America Spasmolytic Injections Revenue Share by Type (2021-2032)
  6. 8.4 North America Spasmolytic Injections Revenue by Application (2021-2032)
  7. 8.4.1 North America Spasmolytic Injections Revenue by Application (2021-2026)
  8. 8.4.2 North America Spasmolytic Injections Revenue by Application (2027-2032)
  9. 8.5 North America Spasmolytic Injections Revenue Share by Application (2021-2032)
  10. 8.6 North America Spasmolytic Injections Revenue by Country
  11. 8.6.1 North America Spasmolytic Injections Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Spasmolytic Injections Revenue by Country (2021-2026)
  13. 8.6.3 North America Spasmolytic Injections Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Spasmolytic Injections Revenue (2021-2032)
  2. 9.2 Europe Spasmolytic Injections Revenue by Type (2021-2032)
  3. 9.2.1 Europe Spasmolytic Injections Revenue by Type (2021-2026)
  4. 9.2.2 Europe Spasmolytic Injections Revenue by Type (2027-2032)
  5. 9.3 Europe Spasmolytic Injections Revenue Share by Type (2021-2032)
  6. 9.4 Europe Spasmolytic Injections Revenue by Application (2021-2032)
  7. 9.4.1 Europe Spasmolytic Injections Revenue by Application (2021-2026)
  8. 9.4.2 Europe Spasmolytic Injections Revenue by Application (2027-2032)
  9. 9.5 Europe Spasmolytic Injections Revenue Share by Application (2021-2032)
  10. 9.6 Europe Spasmolytic Injections Revenue by Country
  11. 9.6.1 Europe Spasmolytic Injections Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Spasmolytic Injections Revenue by Country (2021-2026)
  13. 9.6.3 Europe Spasmolytic Injections Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Spasmolytic Injections Revenue (2021-2032)
  2. 10.2 China Spasmolytic Injections Revenue by Type (2021-2032)
  3. 10.2.1 China Spasmolytic Injections Revenue by Type (2021-2026)
  4. 10.2.2 China Spasmolytic Injections Revenue by Type (2027-2032)
  5. 10.3 China Spasmolytic Injections Revenue Share by Type (2021-2032)
  6. 10.4 China Spasmolytic Injections Revenue by Application (2021-2032)
  7. 10.4.1 China Spasmolytic Injections Revenue by Application (2021-2026)
  8. 10.4.2 China Spasmolytic Injections Revenue by Application (2027-2032)
  9. 10.5 China Spasmolytic Injections Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Spasmolytic Injections Revenue (2021-2032)
  2. 11.2 Asia Spasmolytic Injections Revenue by Type (2021-2032)
  3. 11.2.1 Asia Spasmolytic Injections Revenue by Type (2021-2026)
  4. 11.2.2 Asia Spasmolytic Injections Revenue by Type (2027-2032)
  5. 11.3 Asia Spasmolytic Injections Revenue Share by Type (2021-2032)
  6. 11.4 Asia Spasmolytic Injections Revenue by Application (2021-2032)
  7. 11.4.1 Asia Spasmolytic Injections Revenue by Application (2021-2026)
  8. 11.4.2 Asia Spasmolytic Injections Revenue by Application (2027-2032)
  9. 11.5 Asia Spasmolytic Injections Revenue Share by Application (2021-2032)
  10. 11.6 Asia Spasmolytic Injections Revenue by Country
  11. 11.6.1 Asia Spasmolytic Injections Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Spasmolytic Injections Revenue by Country (2021-2026)
  13. 11.6.3 Asia Spasmolytic Injections Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Spasmolytic Injections Revenue (2021-2032)
  2. 12.2 SAMEA Spasmolytic Injections Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Spasmolytic Injections Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Spasmolytic Injections Revenue by Type (2027-2032)
  5. 12.3 SAMEA Spasmolytic Injections Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Spasmolytic Injections Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Spasmolytic Injections Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Spasmolytic Injections Revenue by Application (2027-2032)
  9. 12.5 SAMEA Spasmolytic Injections Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Spasmolytic Injections Revenue by Country
  11. 12.6.1 SAMEA Spasmolytic Injections Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Spasmolytic Injections Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Spasmolytic Injections Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst